Form 4: Disc Medicine Director Kevin Bitterman Acquires 10,000 Stock Options

Director Kevin Bitterman acquired 10,000 stock options in Disc Medicine, Inc. on June 12, 2024.

Summary

• Kevin Bitterman, a director of Disc Medicine, Inc., acquired 10,000 stock options on June 12, 2024.
• The exercise price of these options is $38.85.
• The options vest on the earlier of the company's 2025 annual meeting or the one-year anniversary of the grant date, contingent upon continued service.
• Following the transaction, Bitterman beneficially owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service, suggesting an expectation of ongoing involvement by the director.

Industry Context

Form 4 filings are standard disclosures for insider transactions and provide transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director can signal confidence to shareholders.

Key Dates